Home
Company
Management Team
Board of Directors
MediciNova History
Careers
Current Openings
Clinical
Development
Development Pipeline
Core Programs
MN-001 (Fibrotic Diseases)
MN-166 (Neurology Diseases)
MN-221 (Respiratory Diseases)
Non-core Programs
MN-001 (Bronchial Asthma)
MN-001 (Interstitial Cystitis)
MN-029 (Cancer)
MN-221 (Preterm Labor)
Information Request
Business
Development
Partners & Collaborators
Information Request
Investor
Relations
Press Releases
Events
Media Archive
Annual Reports
SEC Filings
Stock Quote – TSE
Stock Quote – Nasdaq
Historical Price Lookup
Investment Calculator
Analyst Coverage
Corporate Governance
Information Request
Presentations
Contact
Us
Japanese Site 日本語
Search the site...
MediciNova
is a
biopharmaceutical company
that is developing
novel therapeutics
with a primary focus on
neurology, respiratory,
and
liver diseases
with
unmet medical needs
.
MN-166 for Neurology Diseases
Progressive Multiple Sclerosis
Amyotrophic Lateral Sclerosis (ALS)
CLICK HERE for COMBAT-ALS Webinar
Drug Dependence
Learn More
MN-221 for Respiratory Diseases
Acute Exacerbations of Asthma
COPD Exacerbations
Learn More
MN-001 for Fibrotic Diseases
Liver Fibrosis (NASH or others)
Pulmonary Fibrosis (IPF)
Learn More
